New data on new and newer drugs at the GU Cancers meeting

A whole host of new data on drugs like sipuleucel-T, enzalutamide, abiraterone, and others was available in the poster sessions at the Genitourinary Cancers Ssympisum in Orlando today.

Much of this new data is based on re-analysis of data subsets from trials already reported and so is of limited clinical significance. It would be impossible to comment in detail on all these studies, so … What we have done below is to try to provide a complete listing of most of the relevant posters with links to the abstracts. In just a very few cases we have added some specific comment.

Be warned. … There is a long list below! And it is by no means a complete list of all the drug trial data presented at this meeting. We have simply tried to pick the data on drugs patients are likely to have most interest in.

Posters about abiraterone acetate (Zytiga):

Posters about enzalutamide (Xtandi):

Posters about sipuleucel-T (Provenge):

Posters about cabazitaxel (Jevtana):

Posters about ARN-509:

Posters about radium-223 dichoride:

Posters about dasatinib (Sprycel):

Posters about aflibercept (Zaltrap):

Posters about cediranib (AZD2171):

6 Responses

  1. I have to admit that I don’t understand much of what is contained in these abstracts. I have a hard time with all the abbreviations and the percentages. It would be nice if we had a “Prostate Cancer Research Terms and Abbreviations for Dummies” book! Abbrfeviations like CI, SI, OS, ECOD, etc., give me a headache!

    All kidding aside, am I correct in concluding that the already-approved treatments (Provenge, Zytiga, and Xtandi) all have value in terms of overall survival (OS) as do the not-yet-approved Ra-223 and ARN-509 while Sprycel, Zaltrap, and cederinab do not seem to have much benefit? I’m not sure if Jevtana has been FDA-approved or not but it also seems to have some utility.

    If I am correct, it is pretty disappointing that there are so few “new” treatments that will help. Even the best of them seem to give you only a few extra months albeit at a very high financial cost. I wonder if those few extra months are worth the financial burden that the survivors are left to contend with.

  2. I meant to say earlier, Mike, thank you for digesting all this and presenting it in such a way that people like me can actually derive some benefit. Even with all your knowledge and expertise, it must be a daunting task! Thanks!

  3. Dear Sitemaster,

    Thank you for your excellent information about the Genitourinary Cancer Symposium in Orlando. Since today it seems to be impossible to look on the complete list of the abstracts of the conference. So it is very helpful that you give us direct links. Thank you!

  4. Jake:

    (1) Yes, your assessment of the products that have a proven survival benefit and those that don’t is correct.

    (2) Cabazitaxel (Jevtana) is an approved drug and has shown a clear but small overall survival benefit when used to treat men who have progressive disease after treatment with docetxel-based chemotherapy.

    (3) It would certainly be great if we could come up with drugs that had far greater survival benefits than those available to date … and if they were so cheap that nearly everyone could afford them with ease (like a dozen eggs).

    I should point out, however, that just 15 years ago there were no drugs at all that had been proven to extend survival for men with metastatic prostate cancer. We now have half a dozen, and there are several more prominsing ones (like ARN-509 and some new immunotherapeutic agents) in the pipeline. The cost issue is a problem, however

  5. Dear Gunterman:

    You should still be able to look at the complete list of abstracts of all the prostate cancer papers being presented at the meeting if you click here.

  6. However, it is really good for the drug companies’ bottom line.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: